Stereotactic low-voltage x-ray irradiation for age-related macular degeneration

British Journal of Ophthalmology

Volumn 95, Issue 2, 2011, Pages 185-188

  Moshfeghi, Darius M ^a   Kaiser, Peter K ^b   Gertner, Michael ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Oraya Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADAVER; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; FEMALE; HUMAN; LOW ENERGY RADIATION; MALE; MONTE CARLO METHOD; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; RADIATION BEAM; RETINA MACULA DEGENERATION; SHORT SURVEY; STEREOTACTIC PROCEDURE; X IRRADIATION;

EQUIPMENT DESIGN; HUMANS; MACULAR DEGENERATION; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79151481849     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.163907     Document Type: Short Survey

References (14)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
3. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
4. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48. e235.
5. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72.
6. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006;141:149-56.
7. Sivagnanavel V, Evans JR, Ockrim Z, et al. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2004;(4):CD004004.
8. Avila MP, Farah ME, Santos A, et al. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina 2009;29:157-69.
9. Avila MP, Farah ME, Santos A, et al. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 2009;93:305-9.
10. Hanlon J, Lee C, Chell E, et al. Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose. Med Phys 2009;36:3671-81.
11. Lee C, Chell E, Gertner M, et al. Dosimetry characterization of a multibeam radiotherapy treatment for age-related macular degeneration. Med Phys 2008;35:5151-60.
12. Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 2007;12:465-77.
13. Parsons JT, Bova FJ, Fitzgerald CR, et al. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994;30:765-73.
14. Archer DB, Gardiner TA. Ionizing radiation and the retina. Curr Opin Ophthalmol 1994;5:59-65.